Larimar Proceeding Toward Accelerated Approval Filing In Friedreich’s Ataxia

Efficacy Data Offset Anaphylaxis Concerns, Analysts Say

 
• By Joseph Haas
  
Rare Disease ribbon
Larimer hopes to win approval of first disease-modifying therapy for Friedreich's ataxia

More from Strategy

More from Business